IP Verse

Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients - EP3531133

The patent EP3531133 was granted to Amgen on Aug 23, 2023. The application was originally filed on May 20, 2015 under application number EP18213926A. The patent is currently recorded with a legal status of "Revoked".

EP3531133

AMGEN
Application Number
EP18213926A
Filing Date
May 20, 2015
Status
Revoked
Jan 24, 2025
Grant Date
Aug 23, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

JAMES POOLEMay 21, 2024CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0623679
DESCRIPTIONWO2004106381
DESCRIPTIONWO2007068354
DESCRIPTIONWO2007131092
DESCRIPTIONWO2008119565
DESCRIPTIONWO2008119566
DESCRIPTIONWO2008119567
DESCRIPTIONWO2010052013
DESCRIPTIONWO2010052014
DESCRIPTIONWO2011051307
DESCRIPTIONWO2012146394
DESCRIPTIONWO9954440
OPPOSITIONWO2010052013

Non-Patent Literature (NPL) Citations (36) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BADER et al., J. Clin. Oncol., (20090000), vol. 27, pages 377 - 384-
DESCRIPTION- BUERGER et al., Journal of Clinical Oncology, (20030000), vol. 21, no. 2, pages 184 - 188-
DESCRIPTION- CRICK, J Mol Biol., (19660000), vol. 19, pages 548 - 55-
DESCRIPTION- ECKERT et al., Lancet, (20010000), vol. 358, pages 1239 - 41-
DESCRIPTION- "GenBank", Database accession no. AAA69966-
DESCRIPTION- GRUPP et al., N. Engl. J. Med., (20130000), vol. 368, no. 16, pages 1509 - 1518-
DESCRIPTION- HOSSE et al., Protein Sci., (20060000), vol. 15, pages 14 - 27-
DESCRIPTION- NEEDLEMAN; WUNSCH, J Mol Biol., (19700000), vol. 48, pages 443 - 53-
DESCRIPTION- NICAISE et al., Protein Sci., (20040000), vol. 13, pages 1882 - 91-
DESCRIPTION- NYGREN; UHLEN, Curr Opin Struct Biol., (19970000), vol. 7, pages 463 - 9-
DESCRIPTION- PORTER et al., N Engl J Med., (20110000), vol. 365, pages 725 - 33-
DESCRIPTION- SKERRA, urr Opin Biotechnol, (20070000), vol. 18, pages 295 - 304-
DESCRIPTION- SMITH; WATERMAN, Adv Appl Math., (19810000), vol. 2, pages 482 - 9-
OPPOSITION- Anonymous, "Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia", History of Changes for Study: NCT01471782, (20130102), XP093190581-
OPPOSITION- Anonymous, "Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia", NCT01471782, (20170208), XP093190598-
OPPOSITION- Anonymous, "Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)", NCT03476239, (20230308), XP093190609-
OPPOSITION- Borowitz M. J., Chan J.K.C., "Chapter 9", WHO Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, (20080101), pages 168 - 178, XP093190626-
OPPOSITION- "Chapters 10 and 16", Murphy Kenneth, Janeway's Immunobiology, 8th ed., Garland Science, Taylor & Francis Group, LLC, (20120101), pages 387 - 428, 669 - 716, ISBN 978-0-8153-4243-4, XP093190557-
OPPOSITION- Molhoj, M. Crommer, S. Brischwein, K. Rau, D. Sriskandarajah, M. Hoffmann, P. Kufer, P. Hofmeister, R. Baeuerle, P.A., "CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis", Molecular Immunology, PERGAMON, GB, GB , (20061201), vol. 44, no. 8, ISSN 0161-5890, pages 1945 - 1953, XP005787198-
OPPOSITION- Locatelli Franco, Zugmaier Gerhard, Rizzari Carmelo, Morris Joan D., Gruhn Bernd, Klingebiel Thomas, Parasole Rosanna, Linderkamp Christin, Flotho Christian, Petit Arnaud, Micalizzi Concetta, Mergen Noemi, Mohammad Abeera, Kormany William N., Eckert Cornelia, Möricke Anja, Sartor Mary, Hrusak Ondrej, Peters Christina, Saha Vaskar, Vinti Luciana, Von Stackelberg Arend, "Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia : A Randomized Clinical Trial", JAMA, American Medical Association, Chicago, IL, Chicago, IL, (20210302), vol. 325, no. 9, doi:10.1001/jama.2021.0987, ISSN 0098-7484, pages 843 - 854, XP093190603
OPPOSITION- Theil Karl S., "Bone Marrow Processing and Normal Morphology", Laboratory Hematology Practice, Wiley, (20120410), pages 279 - 299, doi:10.1002/9781444398595.ch22, XP093190640
OPPOSITION- Weisser, N.E. ; Hall, J.C., "Applications of single-chain variable fragment antibodies in therapeutics and diagnostics", BIOTECHNOLOGY ADVANCES., ELSEVIER PUBLISHING, BARKING., GB, GB , (20090701), vol. 27, no. 4, doi:10.1016/j.biotechadv.2009.04.004, ISSN 0734-9750, pages 502 - 520, XP026127899
OPPOSITION- R Handgretinger, G Zugmaier, G Henze, H Kreyenberg, P Lang, A Von Stackelberg, "Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia", Leukemia, Stockton Press, (20110101), vol. 25, no. 1, doi:10.1038/leu.2010.239, ISSN 08876924, pages 181 - 184, XP055034382
OPPOSITION- S.‐H. LEE; W. N. ERBER; A. PORWIT; M. TOMONAGA; L. C. PETERSON, "ICSH guidelines for the standardization of bone marrow specimens and reports", INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, Wiley-Blackwell Publishing Ltd., GB; US, GB; US , (20080904), vol. 30, no. 5, doi:10.1111/j.1751-553X.2008.01100.x, ISSN 1751-5521, pages 349 - 364, XP072389124
OPPOSITION- Bain Barbara J, Bailey Katharine, "Pitfalls in obtaining and interpreting bone marrow aspirates: to err is human", Journal of Clinical Pathology, BMJ Publishing Group, GB, GB , (20101222), vol. 64, no. 5, doi:10.1136/jcp.2010.080820, ISSN 0021-9746, pages 373 - 379, XP093190566
OPPOSITION- Vardiman James W., Thiele Jüergen, Arber Daniel A., Brunning Richard D., Borowitz Michael J., Porwit Anna, Harris Nancy Lee, Le Beau Michelle M., Hellström-Lindberg Eva, Tefferi Ayalew, Bloomfield Clara D., "The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes", Blood, American Society of Hematology, US, US , (20090730), vol. 114, no. 5, doi:10.1182/blood-2009-03-209262, ISSN 0006-4971, pages 937 - 951, XP093190631
OPPOSITION- Topp Max, Dlugosz-Danecka Monika, Skotnicki Aleksander B., Salogub Galina, Viardot Andreas, Klein Andreas K., Hess Georg, Michel Christian S., Grosicki Sebastian, Gural Alex, Schwarz Sylvia E., Pietzko Kerstin, Gärtner Ulrike, Strassz András, Alland Leila, Mayer Jiri, "Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies", TRIALS, BIOMED CENTRAL, LONDON, GB, GB , (20230101), vol. 24, no. 1, doi:10.1186/s13063-022-06982-7, ISSN 1745-6215, XP093190648
OPPOSITION- Gore Lia, Zugmaier Gerhard, Handgretinger Rupert, Locatelli Franco, Trippett Tanya M., Rheingold Susan R., Bader Peter, Borkhardt Arndt, Cooper Todd Michael, O'brien Maureen Megan, Zwaan Christian M., Fischer Anja, Whitlock James, Von Stackelberg Arend, "Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic leukemia (ALL).", Journal of Clinical Oncology, Grune & Stratton, United States, United States, (20130520), vol. 31, no. 15_suppl, doi:10.1200/jco.2013.31.15_suppl.10007, ISSN 0732-183X, pages 10007 - 10007, XP093190578
OPPOSITION- Lindsey M. Hoffman, Lia Gore, "Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications", Frontiers in Oncology, (201403), vol. 4, doi:10.3389/fonc.2014.00063, XP055548630
OPPOSITION- Chiaretti Sabina, Zini Gina, Bassan Renato, "DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA", Mediterranean journal of hematology and infectious diseases, IT, IT , (20140101), vol. 6, no. 1, doi:10.4084/mjhid.2014.073, ISSN 2035-3006, page e2014073, XP093190632
SEARCH- "BACKGROUND INFORMATION FOR THE PEDIATRIC SUBCOMMITTEE OF THE ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING 04 DECEMBER 2012", (20121204), URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM330210.pdf, (20150717), XP055203294 [X] 1-15 * the whole document * * In particular: pp. 4-6, executive summary; Fig. 1; Table 1; Appendix A. *-
SEARCH- Jan Stary ET AL, "Results of the Randomized I-BFM-SG Trial "Acute Lymphoblastic Leukemia Intercontinental-BFM 2002" in 5060 Children Diagnosed in 15 Countries on 3 Continents", (20110918), pages 397 - 398, URL: https://ash.confex.com/ash/2011/webprogram/Paper40820.html, (20150717), XP055203224 [A] 1-15 * the whole document *-
SEARCH- DIRK NAGORSEN ET AL, "Blinatumomab: A historical perspective", PHARMACOLOGY & THERAPEUTICS, (20121201), vol. 136, no. 3, doi:10.1016/j.pharmthera.2012.07.013, ISSN 0163-7258, pages 334 - 342, XP055112692 [A] 1-15 * the whole document * * In particular: p. 340-341, items 9-11. *
SEARCH- VISSER J H ET AL, "Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia", PEDIATRIC HEMATOLOGY AND ONCOLOGY, TAYLOR AND FRANCIS, GB, (20010101), vol. 18, no. 3, doi:10.1080/08880010151114804, ISSN 0888-0018, pages 187 - 191, XP008177028 [A] 1-15 * the whole document * * In particular: Title; Abstract; Methods section. *
SEARCH- G. BASSO ET AL, "Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow", JOURNAL OF CLINICAL ONCOLOGY, (20091005), vol. 27, no. 31, doi:10.1200/JCO.2008.20.8934, ISSN 0732-183X, pages 5168 - 5174, XP055203226 [A] 1-15 * the whole document * * In particular: Title; Abstract; Patients and methods section; p. 5170, 2nd column, 2nd paragraph and table 1. *
SEARCH- G. TALLEN ET AL, "Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90", JOURNAL OF CLINICAL ONCOLOGY, (20100412), vol. 28, no. 14, doi:10.1200/JCO.2009.25.1983, ISSN 0732-183X, pages 2339 - 2347, XP055203293 [A] 1-15 * the whole document * * In particular: Title; Abstract; Patients and methods section. *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents